

September 13, 2017 - Press Release

Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines

Epalinges, Switzerland, September 13, 2017 – Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that they will present new preclinical data. The new data demonstrates that nasal powder, oral capsules and sublingual tablets developed by MACIVIVA partners, containing Mymetics HIV-1 virosome based vaccine candidate, could induce specific antibody immune response in rodent and mini-pig animal models.

The results are generated under the MACIVIVA project, an EU Horizon 2020 project, which stands for “Manufacturing process for Cold-chain Independent Virosome-based Vaccines”. The project started in May 2015, with a duration of total 3.5 years and brings together leading contract manufacturers and the relevant expertise for spray drying, freeze drying and analytical techniques from the pharmaceutical industry to develop a scalable manufacturing process to achieve thermostable and cold-chain independent virosome based vaccines.

The new preclinical data will be presented at three upcoming events.

- 12 – 14 September, 2017: Modern Vaccines Adjuvants & Delivery Systems, Porto, Portugal.
- 16 – 18 September, 2017: ILS Liposome Advances & Liposome Research, Athens, Greece.
- 10 – 12 October, 2017: World Vaccine Congress Europe, Barcelona, Spain.

The preliminary results are showing that spray drying and lyophilization may conserve the virosome structure and antigens during the manufacturing process. Preclinical studies showed that Mymetics HIV-1 vaccine candidate, after being downstream processed into different powder solid dosage forms, could trigger specific antibodies, which were variable depending on the formulation. Antibodies were quantified in serum, nasal washes, vaginal washes and feces by the immuno-PCR Imperacer® assays.

Although this is a first study, the manufacturing process and vaccine formulations will need optimization prior moving forward into GMP development, the data are promising for achieving thermostable and cold-chain independent virosome based vaccines.

About Mymetics

Mymetics Corp. (MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious diseases. It currently has five vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, Malaria, Chikungunya, Herpes Simplex Virus and the RSV vaccine. HIV, malaria and intra-nasal influenza vaccines have successfully finished Phase 1 clinical trials, while the others are in the pre-clinical phase.

Mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Mymetics’ vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, in combination with humoral and cellular immune responses as a second-line defense, which can be essential for the development of an effective vaccine.



Mymetics' unique approach is being validated through partnerships with leading pharmaceutical or research organizations, including projects with PATH-MVI and the Bill and Melinda Gates Foundation.

For further information, please visit www.mymetics.com.

About MACIVIVA

The MACIVIA project is funded as part of Horizon 2020, the European Union research and innovation framework program and by the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners. The €8.4 million grants are funding the evaluation, development and manufacturing scale-up of thermostable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates.

Mymetics acts as coordinator and works with the consortium partners, Catalent UK Swindon Zydis Ltd, Chimera Biotec GmbH (Germany), Upperton Ltd. (UK) and Bachem AG (Switzerland).

This project is funded under the European Union's Horizon 2020 research and innovation programme under Grant Agreement No 646122.  More information: www.maciviva.com

CONTACT:

Mymetics Corporation

Ronald Kempers

Chief Executive Officer

Tel: +41 21 653 4535

Forward looking statements

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.